Corporate Banner
Satellite Banner
Chemical Process Scale Up
Scientific Community
Become a Member | Sign in
Home>News>This Article

GZP Announces Enhanced Biosimilars and Personalized Medicine Initiatives for its Clients

Published: Tuesday, November 20, 2012
Last Updated: Monday, November 19, 2012
Bookmark and Share
Company is expanding its capabilities in helping its clients develop biosimilars and drug device personalized medicine programs.

GZP is announcing expansion of its longstanding capabilities in helping its clients develop biosimilars and drug or biologic/diagnostic device personalized medicine programs for FDA and EMA review.

New legislative initiatives in the US and subsequent regulations and guidelines have provided a number of pathways for development of biosimilars, with the associated requirements for intensive planning and execution of nonclinical and clinical programs.

GZP's CMC, pharmacology/ toxicology, clinical and regulatory experts are available to assist firms in navigating the complexities of such programs.

GZP has been working with firms in Australasia, the US and Europe to develop and test prognostic/diagnostic devices and test methodologies, including genetic testing and identification of biomarkers, for use during clinical trials and post approval therapy.

The selection of appropriate candidates for clinical trials, as well as for specific commercial treatments are important in the personalized medicine and reimbursement arenas.

Regulatory success can be enhanced by assuring that new clinical trial initiatives are carried through to the review and approval process and GZP works with clients to achieve this goal.

Dr. Evan B. Siegel, GZP's CEO, will be in Kuala Lumpur (November 17-22), and will be pleased to meet with interested parties by individual arrangement in Malaysia.

In 2012, GZP increased its global client base across therapeutic areas such as oncology, ophthalmology, and endocrine disease.

The firm created and submitted several INDs and facilitated many meetings and other communications with the FDA, leading to rapid movement of client programs.

GZP believes that early, frequent, targeted, and creative FDA communication leads to successful product development and attracts investors in today's financial climate.

According to Evan Siegel, "We are pleased that firms are still generating promising diagnostic and therapeutic products in the biotechnology and pharmaceutical spaces. Our clients believe that data speak strongly to regulators and we provide sophisticated and intensive help towards that end. The continued success of our business is attributable to our long-term clients, repeat business, and referrals, as well as the stability of our team. This provides an integrated and client-specific approach to delivering the highest quality regulatory and product development services."

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Scientific News
Chemical Design Made Easier
Rice University scientists prepare elusive organocatalysts for drug and fine chemical synthesis.
2015 ACS GCI Pharmaceutical Roundtable Research Grant
Request for proposals: Greener Continuous Chemistry & Engineering Technology.
'Crumpled' Filter to Slash Energy Consumption
Scientists have developed an ultra-thin, super-strong membrane to filter liquids and gases, with the potential to cut energy consumption in industry.
Tackling Chemical Safety Rules and Regulations
Helsinki Chemicals Forum continues to lead international chemicals safety and management discussions.
Pioneering New Method to Map Enzyme Activity
Cardiff University researchers new discovery could have wide-reaching implications for the creation of manufactured goods, biofuels and therapeutic drugs.
Euro Vision turns Reality for Australia’s Iconic ‘Green Whistle’
Patients will soon benefit from a unique invention, with emergency pain killer Penthrox receiving initial regulatory approval for sale in the European and UK markets.
Gaining the Full Benefit of Microflow Electrolysis Cells
This paper sets out the factors that should be considered in seeking good performance from microflow cells for organic electrosynthesis.
Are Chemical Safety Regulations Changing Your Laboratory?
GHS changes to country chemical regulations affect everyone.
Continuous Flow of Breakthroughs for Vapourtec
Flow chemistry systems designed and manufactured by Vapourtec have recently reached the milestone of having been cited in 150 peer review publications.
A Continuous Flow System for the Measurement of Ambient Nitrogen Oxides
The proposed method can be used in industrial locations to continuously monitor ambient NOx levels and it can be automated for measuring the variation of NOx concentrations.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos